Flagship Pioneering Inc. Moderna, Inc. Transaction History

Flagship Pioneering Inc.

$589 Million
Q3 2024

A detailed history of Flagship Pioneering Inc. transactions in Moderna, Inc. stock. As of the latest transaction made, Flagship Pioneering Inc. holds 4,632,149 shares of MRNA stock, worth $182 Million. This represents 52.54% of its overall portfolio holdings.

Number of Shares

4,632,149

Previous 4,632,149 -0.0%

Holding current value

$182 Million

Previous $550 Million 43.72%

% of portfolio

52.54%

Previous 65.75%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$101.21 - $166.61 $509 Million - $839 Million	-5,033,889 Reduced 52.08%	4,632,149 $550 Million
Q4 2023 Feb 14, 2024	SELL	$69.51 - $104.43 $224 Million - $336 Million	-3,220,705 Reduced 24.99%	9,666,038 $961 Million
Q2 2022 Aug 15, 2022	SELL	$117.13 - $176.59 $550 Million - $829 Million	-4,694,273 Reduced 26.7%	12,886,743 $1.84 Billion
Q3 2021 Nov 15, 2021	SELL	$221.9 - $484.47 $666 Million - $1.45 Billion	-3,000,000 Reduced 14.58%	17,581,016 $6.77 Billion
Q1 2021 May 17, 2021	SELL	$109.18 - $185.98 $1.12 Billion - $1.91 Billion	-10,290,508 Reduced 33.33%	20,581,016 $2.7 Billion
Q3 2020 Nov 16, 2020	SELL	$54.34 - $94.85 $489 Million - $854 Million	-9,000,000 Reduced 22.57%	30,871,524 $2.18 Billion
Q2 2020 Aug 13, 2020	SELL	$29.67 - $80.0 $326 Million - $880 Million	-11,000,000 Reduced 21.62%	39,871,524 $2.56 Billion
Q4 2019 Feb 13, 2020	SELL	$13.93 - $21.28 $111 Million - $169 Million	-7,935,855 Reduced 13.49%	50,871,524 $995 Million
Q4 2018 Feb 13, 2019	BUY	$13.52 - $18.8 $795 Million - $1.11 Billion	58,807,379 New	58,807,379 $898 Million

Others Institutions Holding MRNA

# of Institutions

953

Shares Held

240M

Call Options Held

10.6M

Put Options Held

18.7M

View Full List

About Moderna, Inc.

Ticker MRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 391,200,000
Market Cap $15.4B
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...

More about MRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Flagship Pioneering Inc., based on Form 13F filings with the SEC.

News

Stay updated on Flagship Pioneering Inc. with notifications on news.

Account

Flagship Pioneering Inc. Moderna, Inc. Transaction History